Boston Scientific (NYSE:BSX) has experienced a 30% surge in stock price over the past year, significantly outpacing the S&P 500’s 9% gain. The stock is currently trading around $100, but analysts suggest it may be overpriced compared to historical metrics and broader market values.
In terms of valuation metrics, Boston Scientific’s price-to-sales ratio is 8.3, well above the S&P 500’s 3.0, and its price-to-earnings ratio stands at 71.4, compared to the S&P’s 26.4. The company has shown a revenue growth rate of 19.4% in the last twelve months, increasing from $15 billion to $18 billion. Its operating margin is 18.5%, higher than the S&P 500’s 13.2%.
As of June 13, 2025, Boston Scientific’s debt stands at $12 billion against a market capitalization of $147 billion, resulting in a debt-to-equity ratio of 8.1%, which is lower than the S&P 500’s 19.9%. The company’s stock has shown mixed performance during past downturns, including a 25.2% decline during the “Inflation Shock” of 2022, similar to the S&P 500’s drop of 25.4%, indicating vulnerability during economic challenges.
